

Hypothesis

## Apoptosis and signalling in acid sphingomyelinase deficient cells

Dan J Sillence

Address: Glycobiology Institute, Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK

E-mail: dan@glycob.ox.ac.uk

Published: 12 November 2001

Received: 25 October 2001

*BMC Cell Biology* 2001, 2:24

Accepted: 12 November 2001

This article is available from: <http://www.biomedcentral.com/1471-2121/2/24>

© 2001 Sillence; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any non-commercial purpose, provided this notice is preserved along with the article's original URL. For commercial use, contact [info@biomedcentral.com](mailto:info@biomedcentral.com)

### Abstract

**Background:** Recent evidence suggests that the activation of a non-specific lipid scramblase during apoptosis induces the flipping of sphingomyelin from the cell surface to the cytoplasmic leaflet of the plasma membrane. Inner leaflet sphingomyelin is then cleaved to ceramide by a **neutral** sphingomyelinase. The production of this non-membrane forming lipid induces blebbing of the plasma membrane to aid rapid engulfment by professional phagocytes. However contrary evidence suggests that cells which are deficient in **acid** sphingomyelinase are defective in apoptosis signalling. This data has been interpreted as support for the activation of acid sphingomyelinase as an early signal in apoptosis.

**Hypothesis:** An alternative explanation is put forward whereby the accumulation of intracellular sphingomyelin in sphingomyelinase deficient cells leads to the formation of intracellular rafts which lead to the sequestration of important signalling molecules that are normally present on the cell surface where they perform their function.

**Testing the hypothesis:** It is expected that the subcellular distribution of important signalling molecules is altered in acid sphingomyelinase deficient cells, leading to their sequestration in late endosomes / lysosomes. Other sphingolipid storage diseases such as Niemann-Pick type C which have normal acid sphingomyelinase activity would also be expected to show the same phenotype.

**Implications of the hypothesis:** If true the hypothesis would provide a mechanism for the pathology of the sphingolipid storage diseases at the cellular level and also have implications for the role of ceramide in apoptosis.

### Background

Recently reported data shed further light on the interrelationships between caspase activation, the scrambling of membrane phospholipid asymmetry and the production of ceramide which can occur during apoptosis signalling. Firstly, since signalling by the caspase cascade can occur very rapidly elucidation of whether ceramide production or caspase activation comes first is of great importance. A large body of evidence now suggests that inhibition of inducer caspases such as FLICE also inhibit

ceramide formation [1–3]. These observations suggest that ceramide generation is downstream of the early signalling events in apoptosis. Moreover, late generation of ceramide indicates that ceramide formation may be a consequence of the execution of apoptosis rather than a signal. During the execution of apoptosis the activation of a non-specific phospholipid membrane scramblase leads to the general disruption of phospholipid asymmetry, the externalisation of phosphatidylserine and membrane blebbing. Membrane blebbing and

phosphatidylserine exposure signal a physiological endpoint since they lead to engulfment by professional phagocytes and rapid clearance from the tissue.

As early as the 1980's it was suggested that ceramide production and membrane blebbing are linked [4]. Allan and co-workers reported that treatment of chicken erythrocytes with  $\text{Ca}^{2+}$  ionophore A21387 led to a loss of membrane phospholipid asymmetry and membrane blebbing presumably through the activation of a non-specific phospholipid scramblase. Scrambling of membrane asymmetry was associated with increases in ceramide by the action of an intracellular sphingomyelinase. More recently, van Blitterswijk and co-workers have found that activation of a non-specific phospholipid scramblase during Fas-mediated apoptosis is responsible for the generation of ceramide [5]. They show that this ceramide is derived from cell surface sphingomyelin and is cleaved due to flipping of external sphingomyelin towards the inner leaflet of the plasma membrane by an intracellular sphingomyelinase. Simultaneously, inner leaflet phosphatidylserine is flipped to the cell surface. Thus ceramide generation may be a consequence of intercellular signalling for phagocytosis of apoptotic cells. Breakdown of sphingomyelin and the production of ceramide may be very important for the changes in cell morphology that occur during apoptosis. In contrast to sphingomyelin, ceramide is a hydrophobic lipid without a polar headgroup that does not form membrane bilayers in aqueous environments. Ceramide formed from the hydrolysis of sphingomyelin is expected to accumulate in the membrane interior and lead to membrane blebbing. Simultaneously, removal of cell surface sphingomyelin also has a destabilising effect since sphingolipids form complexes (rafts) with cholesterol. This is due to hydrogen bonding between the hydroxyl group of cholesterol and the hydroxyl group of the sphingosine backbone as well as hydrophobic van der Waals interactions with the saturated acyl chains that tend to be enriched in sphingolipids. These changes would be expected to be important in facilitating the changes in membrane curvature that occur during blebbing allowing rapid phagocytosis and by-passing the potentially damaging inflammation that occurs during necrotic cell death. However, recent evidence that acid sphingomyelinase deficient cells have defects in apoptotic signalling pathways have been interpreted as strong evidence for the role of ceramide in signalling. This is despite disparate results with acid sphingomyelinase deficient cells [6]. Indeed it has been observed that splenocytes derived from a NPD mouse in which the acid sphingomyelinase gene has been knocked out can show enhanced apoptosis at advanced stages of the disease [7]. Still it has been claimed that these paradoxical results are due to abnormally large levels of sphingomyelin accumulation in older mice and that

young mice that do not store large amounts of sphingomyelin are defective in apoptosis [8]. These results have been interpreted to support the activation of a sphingomyelinase in a signalling cascade that is an important initial event in apoptosis ie before the activation of inducer caspases [9–11]. In order to clarify some of these issues the following hypothesis is proposed:

### **Presentation of the hypothesis**

#### ***An alternative explanation for the observed defects in apoptosis signalling in acid sphingomyelinase deficient cells***

It is hypothesised that changes in apoptosis signalling in these cells are due to indirect effects of decreased sphingomyelin breakdown rather than the inhibition of ceramide formation. Recent evidence suggests that sphingolipid-enriched rafts form sorting platforms for specific proteins and lipids in the endocytic pathway perhaps especially in the endocytic sorting of specific membrane components to the Golgi apparatus [12,13]. Lysosomal accumulation of sphingomyelin is expected to disrupt endocytic trafficking of important raft-associated cell surface signalling molecules. Sphingomyelin is usually rapidly broken down in the late endosomes and lysosomes. In acid sphingomyelinase deficient cells sphingomyelin can be kinetically trapped in this organelle even in young mice which do not store large amounts of sphingomyelin. Through its association with cholesterol this leads to the formation of rafts in the late endosomes and disruption of the normal trafficking of raft associated proteins and lipids.

### **Testing the hypothesis**

Defects in apoptosis signalling would be expected to occur in other sphingolipid storage disorders, such as glycosphingolipid storage disorders and Niemann-Pick type C which are not defective in sphingomyelinase. Cells storing large amounts of sphingolipid should show changes in the subcellular location of signalling molecules, especially those which are associated with rafts [14].

### **Implications of the hypothesis**

The accumulation of sphingomyelin in the lysosome of these cells may have diverse consequences for the cell's biology including the increased localisation of raft-associated proteins which normally cycle through the early endocytic pathway and Golgi apparatus with the lysosome [12,13]. Such an effect may be expected to lead to reduced surface expression of raft-associated receptors and their effectors. Inhibition of acid sphingomyelinase induces a lipid traffic jam and may lead to the sequestration and consequent inactivation and breakdown of raft-associated proteins in the lysosome. Such events may contribute indirectly to decreased apoptotic signalling.

If true, the evidence suggests a role for ceramide in the blebbing of apoptotic cells in the execution phase of apoptosis to aid their rapid clearance by professional phagocytes. This role is in contrast to the structurally related lipid, diacylglycerol, which serves as a second messenger in many agonist stimulated events.

## References

1. Silence DJ, Allan D: **Evidence against an early signalling role for ceramide in Fas-mediated apoptosis.** *Biochem. J* 1997, **324**:29-32
2. Tepper AD, de Vries E, van Blitterswijk WJ, Borst J: **Ordering of ceramide formation, caspase activation, and mitochondrial changes during CD95- and DNA damage-induced apoptosis.** *J Clin Invest* 1999, **103**:971-978
3. Pronk GJ, Ramer K, Amiri P, Williams LT: **Requirement of an ICE-like protease for induction of apoptosis and ceramide generation by REAPER.** *Science* 1996, **271**:808-810
4. Allan D, Thomas P, Limbrick AR: **Microvesiculation and sphingomyelinase activation in chicken erythrocytes treated with ionophore A23187 and Ca<sup>2+</sup>.** *Biochim Biophys Acta* 1982, **693**:53-67
5. Tepper AD, Ruurs P, Wiedmer T, Sims PJ, Borst J, van Blitterswijk WJ: **Sphingomyelin hydrolysis to ceramide during the execution phase of apoptosis results from phospholipid scrambling and alters cell-surface morphology.** *J Cell Biol* 2000, **150**:155-164
6. Levade T, Jaffrezou JP: **Signalling sphingomyelinases: which, where, how and why?** *Biochim Biophys Acta* 1999, **1438**:1-17
7. Nix M, Stoffel W: **Perturbation of membrane microdomains reduces mitogenic signaling and increases susceptibility to apoptosis after T cell receptor stimulation.** *Cell Death Differ* 2000, **7**:413-424
8. Lozano J, Morales A, Cremesti A, Fuks Z, Tilly JL, Schuchman E, Gulbins E, Kolesnick R: **Niemann-Pick Disease versus acid sphingomyelinase deficiency.** *Cell Death Differ* 2001, **8**:100-103
9. Zhang Y, Mattjus P, Schmid PC, Dong Z, Zhong S, Ma WY, Brown RE, Bode AM, Schmid HH: **Involvement of the acid sphingomyelinase pathway in uva-induced apoptosis.** *J Biol Chem* 2001, **276**:11775-11782
10. Cremesti A, Paris F, Grassme H, Holler N, Tschopp J, Fuks Z, Gulbins E, Kolesnick R: **Ceramide enables fas to cap and kill.** *J Biol Chem* 2001, **276**:23954-23961
11. Grassme H, Jekle A, Riehle A, Schwarz H, Berger J, Sandhoff K, Kolesnick R, Gulbins E: **CD95 signaling via ceramide-rich membrane rafts.** *J Biol Chem* 2001, **276**:20589-20596
12. Simons K, Gruenberg J: **Jamming the endosomal system: lipid rafts and lysosomal storage diseases.** *Trends Cell Biol* 2000, **10**:459-462
13. Pagano RE, Puri V, Doniguez M, Marks DL: **Membrane Traffic in Sphingolipid Storage Disease.** *Traffic* 2000, **1**:807-815
14. Ko YG, Lee JS, Kang YS, Ahn JH, Seo JS: **TNF-alpha-mediated apoptosis is initiated in caveolae-like domains.** *J Immunol* 1999, **162**:7217-7223

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMedcentral will be the most significant development for disseminating the results of biomedical research in our lifetime."

Paul Nurse, Director-General, Imperial Cancer Research Fund

Publish with **BMC** and your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours - you keep the copyright

Submit your manuscript here:

<http://www.biomedcentral.com/manuscript/>



BioMedcentral.com

[editorial@biomedcentral.com](mailto:editorial@biomedcentral.com)